Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06602024 · ClinicalTrials.gov registry record · Phase 3
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
A Phase 3 study, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 3
- Development phase
- 40,817
- Enrollment target
NCT06602024 is a Phase 3 study that has completed, run by ModernaTX. The registered enrollment target is 40,817 participants.
The verdict
NCT06602024, a Phase 3 study, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 40,817 participants
- Enrollment target
Study Summary
The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of mRNA-1010 versus an active comparator against reverse transcription polymerase chain reaction (RT-PCR)-confirmed protocol-defined influenza-like illness (ILI) caused by any influenza A or B strains.
Interventions
- BIOLOGICAL mRNA-1010
- BIOLOGICAL Fluarix®
- BIOLOGICAL Influsplit® Tetra
- BIOLOGICAL Fluarix Tetra
- BIOLOGICAL Alpharix® Tetra
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40,817 participants |
| Start Date | 2024-09-16 |
| Est. Completion | 2025-08-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06602024
The ClinicalTrials.gov registry entry for NCT06602024 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 40,817 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which mRNA-1010 is the first listed.
NCT06602024 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06602024 about?
NCT06602024 is a clinical study titled "A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age". The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of mRNA-1010 versus an active comparator against reverse transcription polymerase chain reaction (RT-PCR)-confirmed protocol-defined influenza-like illness...
What is the current status of trial NCT06602024?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 40,817 participants. The study started on 2024-09-16. Estimated completion is 2025-08-21.
What interventions are being tested in trial NCT06602024?
The interventions under investigation include: mRNA-1010 (BIOLOGICAL), Fluarix® (BIOLOGICAL), Influsplit® Tetra (BIOLOGICAL), Fluarix Tetra (BIOLOGICAL), Alpharix® Tetra (BIOLOGICAL).
Who is sponsoring clinical trial NCT06602024?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.